Potomac, MD, United States of America

Albert B Deisseroth

This inventor holds 32 USPTO granted patents and 5 published patent applications, plus 2 CIPO patents and 3 EPO patents. Top assignees: Microvax, LLC, Vaxum, LLC, Yale University. Active years: 2007-2025.

USPTO Granted Patents = 32 

% Patents Active = 21.9

 

 

Average Co-Inventor Count = 1.4

ph-index = 4

Forward Citations = 65(Granted Patents)


Location History:

  • San Diego, CA (US) (2007 - 2017)
  • Potomac, MD (US) (2012 - 2023)

Company Filing History:


Years Active: 2007-2025

Loading Chart...
Loading Chart...
Loading Chart...
Areas of Expertise:
SARS-CoV-2 Vaccine
Cancer Therapy
Burkholderia Pseudomallei
Tuberculosis Composition
CD40 Ligand Fusion Protein
Adenoviral Vector Vaccine
Dengue Virus Vaccine
Malaria Vaccine
Herpes Simplex Virus
Ebola Virus Vaccine
Mucin Antigen Vaccine
Oncolytic Virus
32 patents (USPTO):Explore Patents

Title: Albert B. Deisseroth: Innovator in Cancer Therapy and Infectious Disease Reduction

Introduction

Albert B. Deisseroth, based in Potomac, MD, is a prolific inventor with 31 patents to his name. His work predominantly focuses on innovative therapies for cancer and the management of infectious diseases. His insights and inventions have contributed significantly to the fields of immunotherapy and infectious disease research.

Latest Patents

Among his latest contributions to science are two impactful patents. The first, titled "Combination Cancer Therapy," introduces a method for treating cancer patients using a combination of two distinct immunotherapy solutions. This method involves administering a checkpoint inhibitor antibody, such as a PD-1 or PD-L1 antibody, through infusion, alongside a TAA/ecdCD40L vaccine component administered subcutaneously. The key aspect lies in the sequential administration of both therapies, enhancing the therapeutic effect compared to administering either solution alone.

The second significant patent, "Burkholderia pseudomallei Composition," is a composition aimed at reducing the virulence of Burkholderia pseudomallei (Bp). This cDNA composition encodes fusion proteins that combine fragments of Bp proteins with a potent immunostimulatory protein, CD40 ligand. This innovative approach seeks to increase levels of neutralizing antibodies, thereby providing protection against lethal challenges posed by Bp.

Career Highlights

Deisseroth’s career includes impactful roles in companies like Microvax, LLC and Vaxum, LLC, where he has applied his expertise in biotechnology and immunotherapy. His extensive experience in these organizations underscores his commitment to advancing medical science through innovative solutions.

Collaborations

Throughout his career, Deisseroth has collaborated with prominent researchers and scientists, including Yucheng Tang and Lixin Zhang. These collaborations have fostered an environment of innovation and have led to significant advancements in several therapeutic areas.

Conclusion

Albert B. Deisseroth's contributions to the fields of cancer treatment and infectious disease management through his patents and collaborations highlight his role as a key innovator in the realm of biotechnology. His ongoing work continues to pave the way for new therapeutic approaches that offer hope for patients facing complex health challenges.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to [email protected]
Loading…